Oligonucleotides for CNS Summit Europe

Europe's oligonucleotide landscape is entering a pivotal growth phase. With the €21M launch of Aerska and major collaborations such as Novartis and SciNeuron, Lundbeck and Contera, and Secarna and Vect-Horus, European biopharma are rapidly advancing RNA-targeted approaches to address previously undruggable CNS diseases.

 

 

In response to this momentum, the inaugural Oligonucleotides for CNS Summit Europe will unite 60+ senior industry leaders for the first European forum dedicated exclusively to CNS-focused Oligonucleotide therapeutics. 

 



The summit delivers three days of highly technical, data-driven discussions addressing the challenges unique to CNS development with insight into next-generation BBB delivery strategies beyond TfR1, advanced in vivo and iPSC models, novel chemistry and conjugation approaches, and translational strategies bridging preclinical data to clinical and regulatory success. 

 



Now is the moment to connect, collaborate, and shape the next wave of RNA-based CNS innovation as the field accelerates globally.